Work

Utility of the 52-Gene Risk Score to Identify Patients With Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy

Year: 2023

Type: conference-abstract

DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6535

Authors: J. Soellner, S. Bentink, C. Hesslinger, T.B. Leonard, M.L. Neely, N.M. Patel, T. Schlange, J.L. Todd, R. Vinisko, M.L. Salisbury

Institutions: Boehringer Ingelheim (Germany), Boehringer Ingelheim (United States), Duke Medical Center, Vanderbilt University Medical Center

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4367607152

Cites:

Cited by:

Related to: 10